Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection

被引：27

作者：

Rabaud, C ^{[1
]}

Bevilacqua, S ^{[1
]}

Beguinot, I ^{[1
]}

Dorvaux, V ^{[1
]}

Schuhmacher, H ^{[1
]}

May, T ^{[1
]}

Canton, P ^{[1
]}

机构：

[1] Ctr Informat & Soins Immunodeficience Humaine, Nancy, Lorraine Champa, France

来源：

CLINICAL INFECTIOUS DISEASES | 2001年 / 32卷 / 10期

关键词：

D O I：

10.1086/320166

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Tolerability of the combination of zidovudine, lamivudine, and nelfinavir used as postexposure prophylaxis (PEP) for HIV infection was prospectively evaluated among 185 patients at 11 hospitals in eastern France. After exclusion of the 106 persons who discontinued PEP either because the source patient subsequently tested HIV seronegative or because the injury was reassessed as resulting in a low risk for transmission of HIV, 67 (85%) of the patients who received such PEP experienced adverse effects, which led to withdrawal of nelfinavir in 28 (35%) of these patients.

引用

页码：1494 / 1495

页数：2

共 50 条

[41] Selecting an Antiretroviral Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis in the Occupational Setting
Tan, Darrell H. S.
Goddey-Erikefe, Blessing
Yoong, Deborah
Naccarato, Mark
McIntyre, Susan
Qureshi, Roohi
Gough, Kevin
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2014, 35 (03): : 326 - 328
[42] CONTINUED ZIDOVUDINE OR DIDANOSINE FOR HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
SAITZ, R
FRIEDMANN, PD
ROBERTS, MS
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (22): : 1598 - 1598
[43] Resistance pathways of human immunodeficiency virus type 1 against the combination of zidovudine and lamivudine
Theys, K.
Deforche, K.
Libin, P.
Camacho, R. J.
Van Laethem, K.
Vandamme, A-M
JOURNAL OF GENERAL VIROLOGY, 2010, 91 : 1898 - 1908
[44] Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
Collier, AC
Coombs, RW
Schoenfeld, DA
Bassett, RL
Timpone, J
Baruch, A
Jones, M
Facey, K
Whitacre, C
McAuliffe, VJ
Friedman, HM
Merigan, TC
Reichman, RC
Hooper, C
Corey, L
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (16): : 1011 - 1017
[45] Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus ribonucleic acid in children and adolescents infected with human immunodeficiency virus
Solder, B
Wintergerst, U
Notheis, G
Eberle, J
Gurtler, L
Belohradsky, BH
JOURNAL OF PEDIATRICS, 1997, 130 (02): : 293 - 299
[46] PSEUDOFAILURE OF ZIDOVUDINE PROPHYLAXIS AFTER A HUMAN-IMMUNODEFICIENCY-VIRUS POSITIVE NEEDLESTICK
LUCEY, D
MILUM, S
LINDQUIST, C
ANDRZEJEWSKI, C
BENTON, J
BOSWELL, RN
JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (05): : 1211 - 1212
[47] Investigations of possible failures of postexposure prophylaxis following occupational exposures to human immunodeficiency virus
Jochimsen, EM
Luo, CC
Beltrami, JF
Respess, RA
Schable, CA
Cardo, DM
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (19) : 2361 - 2363
[48] Prevention of Human Immunodeficiency Virus and AIDS Postexposure Prophylaxis (Including Health Care Workers)
Beekmann, Susan E.
Henderson, David K.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2014, 28 (04) : 601 - +
[49] Postexposure prophylaxis for human immunodeficiency virus: Frequency of initiation and completion of newly recommended regimen
Sepkowitz, KA
Rivera, P
Louther, J
Lim, S
Pryor, B
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1998, 19 (07): : 506 - 508
[50] Frequency of percutaneous injuries requiring postexposure prophylaxis for occupational exposure to human immunodeficiency virus
Sistrom, MG
Coyner, BJ
Gwaltney, JM
Farr, BM
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1998, 19 (07): : 504 - 506

← 1 2 3 4 5 →